Quick read

TR mechanism determines the management pathway

The same severe TR grade can mean very different things. Primary structural TR, secondary ventricular functional TR, device lead-associated TR, and atrial functional TR follow different clinical pathways. Before applying intervention criteria, define the mechanism.

An echo report confirms severe TR. The next question is not only 'how severe?' — it is 'why is it happening?' Is the valve apparatus directly abnormal? Is RV dilation driving leaflet tethering? Is a device lead interfering with leaflet closure? Or is long-standing AF and RA enlargement dilating the annulus? Same severity grade — different pathway.

Key takeaway

TR management starts with mechanism. Primary structural TR, secondary ventricular functional TR, device lead-associated TR, and atrial functional TR should not be pushed through the same intervention algorithm.

Key points

  • Primary structural TR is caused by direct pathology of the tricuspid valve apparatus — leaflets, chordae, papillary muscles, or annulus.
  • Secondary ventricular functional TR is driven by RV dilation, RV dysfunction, pulmonary hypertension, or left-sided heart disease causing annular dilation and leaflet tethering.
  • Atrial functional TR is driven mainly by AF, RA enlargement, and annular dilation — often with relatively preserved RV systolic function.
  • Device lead-associated TR is a separate mechanism, not a subtype of secondary functional TR: the lead mechanically interferes with the leaflets or chordae. Lead presence alone does not prove causality, and functional TR can coexist.
  • The wrong mechanism leads to the wrong pathway.
  • Mechanism guides the evaluation pathway, but final decisions still depend on symptoms, RV function, venous congestion, pulmonary pressure, end-organ effects, procedural risk, and valve-team assessment.
  • The TR Intervention Navigator first asks for confirmed severe TR and a defined mechanism; only then does mechanism select the pathway.

When to read this

Read this when an echo report shows significant or severe TR and you need to decide which evaluation pathway applies. It is especially useful when the mechanism is not clearly stated — or when the patient has AF, a pacemaker or ICD lead, RV enlargement, pulmonary hypertension, or left-sided valve disease.

Primary structural TR: the valve apparatus is the problem

In primary structural TR, the tricuspid valve apparatus itself is abnormal. The problem may involve the leaflets, chordae, papillary muscles, or annulus.

Common causes include leaflet prolapse, flail leaflet, myxomatous degeneration, endocarditis, rheumatic disease, radiation heart disease, carcinoid syndrome, and trauma.

On echo, the mechanism is often visible: prolapse, flail, perforation, leaflet destruction, thickening, or restricted motion. The management pathway is valve-centered, with attention to symptoms, RV function, right-sided remodeling, and systemic venous congestion.

Secondary ventricular functional TR: the RV is driving the regurgitation

In secondary ventricular functional TR, the leaflets are usually structurally normal or only mildly abnormal. The regurgitation occurs because RV dilation, RV dysfunction, pulmonary hypertension, or left-sided heart disease enlarges the tricuspid annulus and tethers the leaflets, causing malcoaptation.

This pathway requires evaluation of the underlying driver: pulmonary hypertension, left-sided valve disease, heart failure, chronic lung disease, or congenital disease. The initial focus is on treating what is producing the RV pressure or volume burden — not on the tricuspid valve itself.

Treating the underlying left-sided disease may improve TR — but this is not guaranteed. Once annular dilation or RV dysfunction is established, TR can persist or progress even after mitral or aortic disease is corrected.

Atrial functional TR: AF and RA remodeling are the main drivers

Atrial functional TR is increasingly recognized in older patients with long-standing AF. The dominant mechanism is RA enlargement and tricuspid annular dilation — with structurally normal leaflets and relatively preserved RV systolic function. This distinguishes it clearly from ventricular functional TR, where RV dilation and dysfunction are central.

Initial management focuses on volume optimization, rate or rhythm control, and heart failure management. In advanced symptomatic severe TR, valve-team assessment may be appropriate. In ACC/AHA 2020, surgical evaluation remains the guideline-centered pathway; transcatheter options such as T-TEER are evolving and should be presented separately from the core guideline pathway.

Device lead-associated TR: the lead may be the mechanism — but prove it

This is a separate mechanism, not a subtype of secondary functional TR. A pacemaker or ICD lead can interfere with the valve in four ways: impingement (the leaflet hits the lead in systole), adhesion (the leaflet is stuck to the lead and moves with it throughout the cycle), perforation, and subvalvular interference with the chordae.

But lead presence alone does not prove lead-caused TR. Look for leaflet restriction and malcoaptation at the exact site of lead contact, and a jet that originates there — 3D echo is often needed. Mechanical interference and functional TR can coexist: the same patient may also have RV dilation, leaflet tethering, RA enlargement, or annular dilation.

When the lead is part of the mechanism, management is planned jointly by the device and valve teams. Decisions about the lead and about the valve depend on each other, and neither team can make them alone.

TR mechanism at a glance
MechanismPrimary driverTypical RV functionManagement focus
Primary structuralLeaflet / apparatus pathologyMay be preserved or volume overloadedValve-centered evaluation
Secondary ventricular functionalRV dilation, PH, left-sided diseaseOften impaired or pressure/volume overloadedTreat underlying cause; assess annulus/RV; consider concomitant repair when relevant
Atrial functionalAF, RA enlargement, annular dilationRelatively preservedRhythm/rate, volume, HFpEF context; valve-team assessment if severe and symptomatic
Device lead-associatedLead-leaflet interaction: impingement, adhesion, perforation, subvalvular interferenceVariableDevice and valve team evaluation; check for coexisting functional TR

How it fits into the TR Intervention Navigator

The TR Intervention Navigator does not start with mechanism. If severe TR has not been confirmed — for example, when severity findings are discordant — or the mechanism is unclear, it returns 'confirm severity and mechanism first.' Once both are confirmed, it checks overriding context (limited life expectancy, planned left-sided surgery), and then the mechanism selects the pathway: device lead-associated TR goes to device-valve team evaluation, atrial functional TR to its own pathway, and primary or secondary TR to valve-center evaluation or surveillance according to symptoms and RV and end-organ status.

That sequence is how the tool organizes its output, not a rule for when to ask for help. A patient with progressive symptoms, RV dysfunction, or venous congestion can be discussed with the valve team — and the device team, if a lead may be involved — while severity is still being confirmed. Final decisions still depend on symptoms, RV function, venous congestion, pulmonary pressure, end-organ dysfunction, procedural risk, and local treatment options.

  1. Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2021;77(4):e25–e197.
  2. Zoghbi WA, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation. J Am Soc Echocardiogr. 2017.
  3. Dreyfus J, et al. Functional Tricuspid Regurgitation: A Need to Redefine. J Am Coll Cardiol. 2020.
  4. Andreas M, Burri H, Prendergast B, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2024;45(5):346–365. doi:10.1093/eurheartj/ehad783

Related valve learning

Apply this in practice

After confirming mechanism, use the TR Intervention Navigator to evaluate the appropriate pathway.

Open TR Intervention Navigator